Correlation between COVID-19 and cancer comorbidity: COVID-19 biomarkers in cancer patients

Abstract

Due to the COVID-19 pandemic, many cancer patients around the globe exhibit difficulties to maintain the treatment they needed. However today, it is well known that the mortality rate of cancer patients is higher when they get COVID-19 infection. For these patients with both COVID-19 and cancer, biomarkers can help prognosis. For some biomarkers, gender differences can be observed which affects the disease severity. Additionally, the review focuses on ACE2 as a biomarker for cancer patients, the receptor SARS-COV-2 uses to enter the host cell. Additionally, the usage of flavonoids can be an alternative treatment method due to their various promising therapeutic properties such as anti-inflammatory, antioxidant, antiproliferative, anti-inflammatory, and anticancer activity. When used for cancer therapy, Flavonoids can play a key role in different mechanisms such as inactivation of carcinogens, cell cycle arrest, antiproliferation, and angiogenesis inhibition. Due to the ability of both ACE2 inhibition and anticancer property, flavonoids can be used as a new treatment strategy for cancer patients with COVID-19. Therefore, it is crucial to understand the relation between COVID-19 and cancer to design new specific treatments.